The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Abiraterone and Enzalutamide for mCRPC

Charles Ryan, MD
Published Online: 12:00 AM, Fri January 31, 2014
Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.

Clinical Pearls

  • The phase III PREVAIL study looked at enzalutamide versus placebo in chemotherapy-naïve, asymptomatic patients with metastatic castration-resistant prostate cancer
  • There was a statistically significant survival benefit and positive prolongation of radiographic progression-free survival in favor of enzalutamide
  • Dr. Ryan believes these data will drive the eventual use of this therapy in the chemotherapy-naïve population
  • Physician prescribing preferences will ultimately determine how abiraterone and enzalutamide are used

<<< Back to the GU 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.